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Abstract  
Introduction: The primary objective of this study was to evaluate the safety and  
tolerability of carboplatin plus pemetrexed for elderly patients (≥75 years) with  
chemotherapy-naïve advanced non-squamous (non-sq) non-small cell lung cancer  
(NSCLC).  
Methods: Patients received escalated doses of carboplatin at an area under the  
concentration-time curve (AUC) of 4 (level 1) or 5 (level 2) plus pemetrexed (500  
mg/m2) every 3 weeks for a maximum of 6 cycles. Dose escalation was decided  
according to whether dose-limiting toxicity (DLT) occurred in the first cycle of  
chemotherapy.   
Results: A total of 20 patients (6 at level 1, 14 at level 2) were enrolled. No DLTs were  
observed in patients at level 1 or the first 6 patients at level 2, and therefore the  
combination of carboplatin at an AUC of 5 plus pemetrexed at 500 mg/m2 was  
considered to be the recommended dose. Among a total of 14 patients in level 2, only  
one patient experienced DLT: grade 3 febrile neutropenia and urticaria. The major  
toxicities were neutropenia, thrombocytopenia, and anemia. Liver dysfunction, fatigue,  
and anorexia were also common, but generally manageable. Six patients showed partial  
responses, giving the overall response rate of 30%. The median progression-free  
survival period was 4.8 months (95% CI 2.9-6.7 months).   
Conclusions: The combination of carboplatin at an AUC of 5 plus pemetrexed at 500  
mg/m2 was determined as the recommended dose in chemotherapy-naïve elderly  
patients (≥75 years) with advanced non-sq NSCLC, in view of overall safety and  
tolerability.   
 
Mini-abstract  
The combination of carboplatin at an AUC of 5 plus pemetrexed at 500 mg/m2  
was determined as the recommended dose in chemotherapy-naïve elderly patients (≥75  
years) with advanced non-sq NSCLC. 
 
 
 
 
 
 
 
 
Introduction  
Lung cancer is the leading cause of cancer death worldwide. Approximately 85%  
of lung cancers are non-small cell types, and approximately 70% of patients with  
non-small-cell lung cancer (NSCLC) already have inoperable, locally advanced or  
metastatic disease at diagnosis (1). As society ages, the ratio of elderly lung cancer  
patients older than 75 years has increased significantly in the lung cancer patient  
population as a whole (2, 3). Platinum-doublet chemotherapies have been established as  
the standard for advanced NSCLC (4-6). However, their efficacy for elderly patients has  
been under-represented in clinical trials, and therefore their role in this setting is still 
not  
clear.  
Previously, some prospective randomized controlled trials for elderly NSCLC  
patients have investigated the optimal forms of chemotherapy for them. The ELVIS trial  
(7) demonstrated that treatment with vinorelbine resulted in better survival and quality  
of life than best supportive care, and another group reported that docetaxel improved  
progression-free survival (PFS), response rate, and disease-related symptoms in  
comparison with vinorelbine (8). Based on these results, the current standard treatment  
for elderly patients with advanced NSCLC is still monotherapy, such as docetaxel or  
vinorelbine. However, subset analyses in some phase III trials have reported that  
platinum-doublet chemotherapies may be feasible and promising for fit elderly patients  
with good performance status (PS) and adequate organ function (9, 10). Recently, a  
phase III trial for elderly patients (≥70 years) with NSCLC comparing the  
carboplatin-paclitaxel combination with monotherapy, such as gemcitabine or  
vinorelbine (IFCT 0501), demonstrated that platinum-doublet chemotherapy yielded  
better survival than monotherapy. Although the toxicities of platinum-doublet 
 
 
 
 
 
 
 
 
 
 
 
chemotherapy are indeed higher, this approach may be promising for elderly NSCLC  
patients (11).   
Pemetrexed is a multitargeting anti-folate chemotherapeutic agent reported to be  
as effective as docetaxel in a second-line setting, with less toxicity (12). Furthermore,  
cisplatin in combination with pemetrexed is now considered to be the standard first-line  
regimen for non-squamous (non-sq) NSCLC based on the results of a previous phase III  
trial (13). Because carboplatin-based regimens have been shown to be less toxic, more  
convenient, they have been widely used as a substitute for cisplatin regimens in clinical  
practice, especially for elderly patients. In a previous dose escalation study of  
carboplatin plus pemetrexed for patients aged <75 years with advanced NSCLC, this  
combination was shown to be effective and less toxic (14). However, the optimal doses  
of carboplatin and pemetrexed for patients aged ≥75 years with advanced non-sq  
NSCLC have not yet been fully evaluated. Therefore, we conducted the present  
prospective study to evaluate the safety and tolerability of this combination therapy for  
elderly patients (≥75 years) with chemotherapy-naïve advanced non-sq NSCLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients and Methods  
Study Design  
This was a dose escalation study of carboplatin in combination with pemetrexed for  
elderly patients aged ≥75 years with chemotherapy-naïve advanced non-sq NSCLC. The  
primary objectives were to estimate the maximum tolerable dose (MTD) and determine  
the recommended dose (RD). The secondary objectives were to determine the response  
rate, PFS, overall survival (OS), and toxicity profiles.   
This study consisted of two parts. Part 1 was the dose escalation phase, and Part 2  
was the expansion phase. In Part 1, 6 patients were treated with carboplatin at an area  
under the concentration-time curve (AUC) of 4 plus pemetrexed at 500 mg/m2 (level 1).  
If 4 of these 6 patients experienced dose-limiting toxicity (DLT), the study was  
terminated. If 3 of the patients or fewer experienced DLT, dose escalation was continued  
to the next level. At dose level 2, 6 patients received carboplatin at an AUC of 5 plus  
500 mg/m2 pemetrexed. If 4 of them experienced DLT, this level was considered to be  
the MTD, and the study was moved to Part 2 at dose level 1. If DLT was observed in 3  
of 6 patients or fewer, the study was moved to Part 2 at dose level 2. In Part 2,  
additional patients, up to a maximum of 14, were enrolled to receive carboplatin plus  
pemetrexed at the doses determined in Part 1. Although dose escalation was decided  
according to whether DLT occurred only in the first cycle of chemotherapy, RD was  
finally decided according to the toxicities observed throughout all of the treatment  
periods.   
  
Eligibility  
Patients with histologically or cytologically confirmed non-sq NSCLC were  
eligible for this study. Each of the patients were required to meet the following criteria:  
(1) clinical stage III (not amenable to radiotherapy), IV, or postoperative recurrence; (2)  
age 75 years or older; (3) measurable lesions on the basis of Response Evaluated  
Criteria in Solid Tumors (RECIST) ver1.0; (4) Eastern Cooperative Oncology Group  
(ECOG) PS of 0-1; (5) no prior chemotherapy for NSCLC, with the following minimum  
intervals since previous treatment: ≥4 weeks after surgery, and ≥4 weeks after curative  
thoracic irradiation or ≥2 weeks after the last irradiation to other organs; (6) adequate  
organ function {white blood cell count (WBC) ≥4000/mm3, neutrophil count  
≥2000/mm3, hemoglobin ≥9.0 g/dl, platelet count ≥100,000/mm3, serum creatinine ≤1.5  
mg/dl, creatinine clearance ≥45 ml/min, serum total bilirubin ≤1.5 mg/dl, aspartate  
aminotransferase (AST) and alanine aminotransferase (ALT) ≤100 U/l, partial pressure  
of arterial oxygen (PaO2) ≥70 mmHg (on room air)}; (7) life expectancy ≥3 months.  
This study was approved by the institutional review board at Kurume University before  
commencement. All patients provided written informed consent before the start of study  
treatments. This study was registered with UMIN (University Hospital Medical  
Information Network in Japan), number UMIN 000003231.  
  
Study treatment  
All patients received 500 mg/m2 pemetrexed by intravenous infusion within 10  
minutes, followed by intravenous infusion of carboplatin over at least 30 minutes (to  
give an AUC of 4 or 5) on day 1 of the 21-day cycle. Carboplatin doses were  
determined using the estimated creatinine clearance (Cockcroft-Gault formula) and the  
Calvert formula based on AUC. Standard antiemetic prophylaxis with intravenous  
5-hydroxytryptamine-3 antagonist and dexamethasone was administered before 
chemotherapy. Combination chemotherapy was repeated every 3 weeks for a maximum  
of 6 cycles. Subsequent cycles of chemotherapy were withheld until the following  
criteria were satisfied: WBC >3000/mm3 or neutrophil count >1500/mm3, platelet count  
≥100000/mm3, PS ≤1, SpO2 ≥95%, AST/ALT ≤100 U/l, total bilirubin ≤1.5 mg/dl,  
serum creatinine ≤1.5 mg/dl, other non-hematological toxicity ≤grade 1. If these criteria  
were unsatisfied within 43 days from day 1 of the current cycle, the patient was  
excluded from further participation. The carboplatin and pemetrexed doses were to be  
reduced from dose level 2 to level 1, or from dose level 1 to an AUC of 4 and 400  
mg/m2, respectively, in the subsequent cycle if toxicity equivalent to DLT occurred.  
Prophylactic administration of granulocyte colony-stimulating factor (G-CSF) was not  
allowed at any time during the study.  
While the patients were being studied, they received supplementary folic acid and  
vitamin B12. All patients underwent comprehensive baseline assessments including  
clinical laboratory tests and imaging studies. Patients also received follow-up  
assessments and monitoring at regular intervals. Toxicity evaluations were based on the  
Common Terminology Criteria for Adverse Events, version 3.0.   
 
 
Definition of DLT  
 DLT was defined as a toxicity occurring in cycle 1 that met one of the following  
criteria and for which a causal relationship with carboplatin or pemetrexed could not be  
ruled out: (1) grade 4 neutropenia lasting 5 days or longer; (2) febrile neutropenia; (3)  
grade 4 thrombocytopenia, grade 3 thrombocytopenia that required platelet transfusion  
or was associated with bleeding; (4) grade 3 or 4 non-hematological toxicity (the  
following events were to be regarded as DLT if they did not recover to ≤grade 2 despite 
standard/optimal supportive treatment: nausea, vomiting, anorexia, fatigue, 
constipation, diarrhea, or transient electrolyte abnormality). If the patients experienced 
toxicities that met the DLT criteria, the treatment doses were modified in subsequent 
courses 
 
Safety and efficacy evaluation  
All patients who received at least one dose of the study treatment were included in  
the safety and efficacy analysis. A maximum of 20 patients were to be enrolled in this  
study to evaluate the safety of the carboplatin and pemetrexed combination. At least 14  
patients were to be treated at the recommended doses. The probability of adverse events  
with incidences equal to or greater than 20% not being detected in any of the 14 patients  
was 4.4%.   
The efficacy endpoints were tumor response, PFS and OS. Tumor response was  
evaluated according to the RECIST guidelines (15). PFS was defined as the period from  
enrollment to the date of confirmation of progressive disease (PD) or the date of death  
due to any cause, whichever was earlier. OS was defined as the period from registration  
until death due to any cause. Patients not known to have died or to have suffered  
progression were censored at the date of the last progression-free assessment. The  
survival data were cut-off by June 2013.  
 
 
Statistical analyses  
The Kaplan-Meier (K-M) method was used for PFS and OS analysis. This included  
generation of the K-M curve and determining the median with the 95% confidence  
interval.  The incidence of adverse events was calculated for each dose group. The  
distribution of best overall response was summarized in the patients who had target 
lesions 
 
 
 
 
 
 
 
 
 
Results  
  
Patient characteristics  
Between March 2010 and November 2012, 20 patients were enrolled into this study  
at Kurume University Hospital. The patients’ characteristics are listed in Table 1. The  
median age was 77 years (range, 75 to 83 years), 13 patients were male and 7 were  
female, and 14 patients (70%) had PS 0-1. All patients had adenocarcinoma histology.  
Epidermal growth factor receptor (EGFR) mutation status was examined in 17 patients.  
Four patients had EGFR mutation (1 had exon 19 deletions, and 3 had a L858R  
missense mutation in exon 21). Nine of these patients had a previous treatment history  
such as pleurodesis, palliative radiotherapy including whole-brain irradiation,  
gamma-knife, and curative thoracic radiotherapy.  
 
 
Determination of recommended dose    
The profiles of the major toxicities observed in cycle 1 are shown in Table 2. In  
Part 1, no DLT was observed in 6 patients at dose level 1. The dose of carboplatin and  
pemetrexed was then escalated to level 2. At dose level 2, no DLT was also observed in  
6 patients. Therefore, although the MTD had not been reached, the RD was assumed to  
be carboplatin at an AUC of 5 plus pemetrexed at 500 mg/m2, and an additional 8  
patients were assigned to this dose level. In total, 14 patients received carboplatin at an  
AUC of 5 plus pemetrexed at 500 mg/m2. Among these 14 patients, only one patient  
experienced DLTs in cycle 1: grade 3 febrile neutropenia, urticaria and grade 4  
thrombocytopenia.  
 
 
Treatment delivery 
 
At dose level 1, for 6 patients who received carboplatin at an AUC of 4 and  
pemetrexed at 500 mg/m2, a total of 23 cycles of combination therapy were delivered  
overall. The median number of cycles was 4 (range 2-6). Two of those patients required  
dose reduction due to adverse events (AEs) in 2 cycles (9% of the total cycles). At level  
2, for 14 patients who recieved carboplatin at an AUC of 5 and pemetrexed at 500  
mg/m2, a total of 48 cycles of combination therapy were delivered overall. The median  
number of cycles was 4 (range 1-6). Four of those patients required dose reduction due  
to AEs in 5 cycles (10% of the total cycles) and dose delays in 2 cycles (4% of the total  
cycles). One patient required dose reduction twice due to AEs. Four patients  
discontinued the study protocol because of AEs (2 due to dose delay after  
thrombocytopenia, one at the investigator’s discretion related to AEs, and patient refusal  
related to AEs, respectively). The major reasons for dose reductions and dose delays  
were hematologic toxicities. The average treatment interval was 25 days. 
 
Toxicities  
The profiles of major toxicities and severe toxicities observed during the entire  
treatment period are shown in Tables 3. All patients (n=20) who received combination  
therapy were assessable for toxicity. The most frequent grade 3 or 4 toxicity was  
hematologic toxicities. Such toxicities ≥grade 3 were neutropenia (55%), anemia (40%),  
thrombocytopenia (40%), and leukopenia (40%). Of these events, grade 4  
thrombocytopenia and grade 3 or 4 anemia were observed in 4 and 8 patients,  
respectively. Among them, transfusion of platelets and red blood cells was performed in  
2 and 5 patients, respectively, throughout the entire study period. G-CSF was  
administered in only one patient who developed febrile neutropenia (a DLT case). On 
the other hand, grade 3 or 4 non-hematological toxicities were febrile neutropenia (5%),  
anorexia (5%) and urticaria (5%). Although non-hematological toxicities were generally  
manageable with supportive care, dose delays or reductions, anorexia and fatigue tended  
to be more frequent than those in non-elderly patients reported previously. No  
treatment-related deaths occurred in this study. 
 
Efficacy  
The efficacy data are shown in Table 4. Among 20 evaluable patients, 6 had partial  
responses (1 patient at dose level 1 and 5 at dose level 2) and 9 had stable disease. The  
overall response rate was 30%, and the disease control rate was 75%. After a median  
follow-up period of 10.1 months (range, 1.3-28.2 months), 7 patients were still alive.  
The median PFS for the patients overall was 4.8 months (95% CI 2.9-6.7 months; fig.1),  
and the median OS was 17.8 months (95% CI 8.6-27.0 months; fig.2). 
 
Post-discontinuation chemotherapy  
Among 18 patients who showed disease progression, 14 (77.8%) received  
second-line chemotherapy, and 4 received only best supportive care due to poor PS. All  
four patients who had EGFR mutation received gefitinib as second-line chemotherapy;  
the rest received docetaxel or erlotinib. 
 
Discussion  
  
We conducted a prospective study to evaluate the safety and tolerability of  
combination chemotherapy with carboplatin and pemetrexed in elderly patients (≥75  
years) with chemotherapy-naïve advanced non-sq NSCLC. Six patients were treated  
with carboplatin at an AUC of 4 (level 1) and pemetrexed at 500 mg/m2, and 14 patients  
received carboplatin at an AUC of 5 (level 2) and pemetrexed at 500 mg/m2. Because  
we had originally planned not to escalate the doses exceeded at dose level 2, we accrued  
a further 8 patients at dose level 2 based on the protocol for Part 2 (expansion phase). In  
Part 2, DLT was observed in 1 patient in the first cycle, and as a result, only 1 out of 14  
patients (7%) finally experienced DLT at dose level 2.   
Next, we evaluated the adverse events of this combination therapy during all  
treatment periods, and found that the incidence of hematologic toxicities, especially  
thrombocytopenia and anemia, was markedly higher than expected. In this study, 6  
(30%) of 20 patients required either platelet or red blood cell transfusion, and 2 (10%)  
were withdrawn from the study due to persistent thrombocytopenia. Although it is very  
difficult to predict the severity of hematological toxicities before the start of treatment,  
it is rare for transfusion to be necessary in the first cycle. With regard to  
non-hematologic toxicities, fatigue and anorexia seemed to be more frequent and  
prolonged than those in younger patients, although their grades were less than 2 and  
these events were well manageable with supportive care. A previous meta-analysis  
comparing single agents with platinum-doublet chemotherapy in elderly patients (≥70  
years) reported that use of platinum-doublet was associated with a higher incidence of  
grade 3 or 4 thrombocytopenia and anemia than was the case for single agents (16). The  
IFCT-0501 study comparing carboplatin-paclitaxel with single agents, such as 
gemcitabine or vinorelbine, also demonstrated that hematological toxicities were more  
frequent in the platinum-doublet chemotherapy group (11). Therefore, the toxicity  
profiles we obtained were consistent with these previous reports.  
The overall response rate of 30%, the median PFS of 4.8 months (95% CI 2.9-6.7  
months), and the median OS of 17.8 months (95% CI 8.6-27.0 months) were thought to  
be encouraging results. A previously reported dose escalation study conducted by  
another group in Japan demonstrated an overall response rate of 47.1%, a median PFS  
of 5.1 months (95% CI 2.4-7.7 months), and a median OS of 16.5 months (95% CI  
7.7-26.9 months) (17). Furthermore, currently reported phase II study of carboplatin and  
pemetrexed for elderly patients (≥70 years) yielded an overall response rate of 28.6%, a  
median PFS of 5.5 months (95% CI 4.7-6.7 months), and a median OS of 10.4 months  
(95% CI 9.1-12.9 months) (18). Although these studies, and our present one, employed  
small sample sizes, they demonstrated an efficacy similar to that in younger patients,  
and therefore the combination of carboplatin and pemetrexed for elderly patients is  
thought to be worth further investigation.  
For non-elderly patients, the recommended dose of this combination was  
carboplatin at an AUC of 6 and pemetrexed at 500 mg/m2, based on a previous dose  
escalation study (14). However, we did not plan to escalate that dose level in the present  
study for the following reasons: First, in the dose escalation study for non-elderly  
patients, hematological toxicities were more frequent for carboplatin at an AUC of 6  
and pemetrexed at 500 mg/m2 than for carboplatin at an AUC of 5 and pemetrexed at  
500 mg/m2. Second, in the phase III study that compared carboplatin plus pemetrexed  
with carboplatin plus gemcitabine, which is one of the standard regimens for NSCLC,  
there was no significant inter-group difference in the OS, in spite of the fact that 
carbopatin was set at an AUC of 5 (19). In addition, we did not plan pemetrexed  
maintenance therapy from the outset because when we originally planned this study in  
2009, the results of pemetrexed maintenance therapy had not been reported, although  
the usefulness of pemetrexed maintenance therapy had been demonstrated in some  
phase III studies (20, 21), and pemetrexed-based induction therapy followed by  
pemetrexed maintenance therapy is now a standard treatment for non-elderly patients  
with non-sq NSCLC. For elderly patients (≥75 years), there are still no definitive data  
regarding maintenance therapy after platinum-doublet induction therapy, and therefore  
this type of maintenance therapy is also worth evaluating in the future. 
On the other hand, patient selection is a very important issue in the elderly  
population, especially patients aged ≥75 years, because most such patients are thought  
to have a natural decline of physiological function and have a potential for more  
comorbidities or to be taking more concomitant medications than younger patients,  
although chronological age is not always an exact indicator of organ function. Recently,  
the Cancer-Specific Geriatric Assessment (CSGA) has been devised, and its usefulness  
reported (22-24), further investigations being ongoing. It is hoped that the CSGA will  
be a helpful tool for selection of fit elderly patients for chemotherapy.  
In conclusion, the combination of carboplatin at an AUC of 5 plus pemetrexed at  
500 mg/m2 was determined as the recommended dose for chemotherapy-naïve elderly  
patients (≥75 years) with advanced non-Sq NSCLC. Our findings provide some  
rationale for the ongoing randomized controlled trial comparing this regimen followed  
by pemetrexed maintenance therapy with docetaxel monotherapy in elderly patients  
(≥75 years) with non-sq NSCLC (UMIN000011460).  
Acknowledgements  
The authors thank all the participants of this study.  
  
Conflicts of interest  
The authors declare no conflicts of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References   
1. Cojean I, Le Chevalier T. Chemotherapy of stage IIIB and IV non-small-cell lung  
cancer. Ann Oncol 1995; 6(Suppl 3): S41-S44.  
2. CANCER STATISTICS IN JAPAN 2013.  
http://ganjoho.jp/professional/statistics/backnumber/2013_jp.html (5 December 2013,  
data last accessed).  
3. SEER Cancer Statistics Review (CSR) 1975-2010  
http://seer.cancer.gov/csr/1975_2010/ (14 June 2013, data last accessed).  
4. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus  
irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin  
plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative  
Study in Japan. Ann Oncol 2007; 18: 317-323.  
5. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing  
three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol  
2002; 20: 4285-4291.  
6.Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy  
regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.  
7. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of Vinorelbine on  
Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell  
Lung Cancer. J Natl Cancer Inst 1999; 91: 66-72. 
8. Kudoh S, Takeda K, Nakagawa K et al. Phase III study of docetaxel compared with  
vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of  
the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;  
24: 3657-3663. 
9. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients  
with advanced non-small-cell lung cancer: implications of Eastern Cooperative  
Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-181.  
10. Goto K,Nishiwaki Y, Saijo N, et al. The Four-Arm Cooperative Study (FACS) for  
advanced non-small cell lung cancer(NSCLC);A subgroup analysis in elderly  
patients(pts). Proc Am Soc Clin Oncol 2006; 24: Abstr 7115  
11. Quoix E, Zalcman G, Oster JP et al. Carboplatin and weekly paclitaxel doublet  
chemotherapy compared with monotherapy in elderly patients with advanced  
non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet Oncol  
2011; 378: 1079-1088.  
12. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed  
versus docetaxel in patients with non-small-cell lung cancer previously treated with  
chemotherapy. J Clin Oncol 2004; 22: 1589-1597.  
13. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus  
gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with  
advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551. 
14. Okamoto I, Takeda K, Daga H et al. Dose-escalation study of pemetrexed in  
combination with carboplatin followed by pemetrexed maintenance therapy for  
advanced non-small cell lung cancer. Lung cancer 2010; 70: 168-173.  
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the  
response to treatment in solid tumors. European Organization for Research and  
Treatment of Cancer, National Cancer Institute of the United States, National Cancer  
Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216. 
16. Des Guetz G, Uzzan B, Nicolas P et al. Comparison of the efficacy and safety of  
single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the  
elderly: a meta-analysis. Crit Rev Oncol Hematol 2012; 84: 340-349.  
17. Tamiya A, Tamiya M, Shiroyama T et al. Dose escalation study of  
carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients  
with advanced nonsquamous nonsmall-cell lung cancer. Ann Oncol 2013; 00: 1-6.  
18. Gervais R, Robinet G, Clément-Duchêne C et al. Pemetrexed and carboplatin, an  
active option in first-line treatment of elderly patients with advanced non-small cell  
lung cancer (NSCLC): a phase II trial. Lung Cancer 2013; 80: 185-190.  
19. Grønberg BH, Bremnes RM, Fløtten O et al. Phase III study by the Norwegian lung  
cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus  
carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin  
Oncol 2009; 19: 3217-3224.  
20. Paz-Ares LG, de Marinis F, Dediu M et al. PARAMOUNT: Final Overall Survival  
Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo  
Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for  
Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2013; 31:  
2895-2902. 
21. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best  
supportive care versus placebo plus best supportive care for non-small-cell lung  
cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 347: 1432-1440.  
22. Hurria A, Gupta S, Zauderer EL et al. Developing a Cancer-Specific Geriatric  
Assessment; A Feasibitity Study. Cancer 2005; 104: 1998-2005. 
23. Extermann M, Hurria A. Comprehensive Geriatric Assessment for Older Patients  
With Cancer. J Clin Oncol 2007; 25: 1824-1831.  
24. McCleary NJ, Wigler D, Berry D et al. Feasibility of Computer-Based  
Self-Administered Cancer-Specific Geriatric Assessment in Older Patients With  
Gastrointestinal Malignancy. Oncologist 2013; 18: 64-72. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
